MedTrace Logo

Silymarin in NAFLD

NCT02973295 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-11-05

No results posted yet for this study

Summary

This study evaluates the influence of Silymarin in reducing laboratory, ultrasonographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive Silymarin (Verum) while the other half will receive placebo

Conditions

  • Non-Alcoholic Fatty Liver Disease

Interventions

DRUG

Silymarin

Capsules contains 100 mg of silymarin

OTHER

Placebo Oral Capsule

Capsule will be identical in shape, size and color, packed in the same way like verum

Sponsors & Collaborators

  • University of Rijeka, Medical Faculty

    collaborator UNKNOWN

  • Belupo

    collaborator OTHER

  • University of Rijeka, Faculty of Health studies

    collaborator UNKNOWN

  • University Hospital Rijeka

    lead OTHER

Principal Investigators

  • Goran Hauser, MD, PhD · Clinical Hospital Centre Rijek, Croatia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-20
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02973295 on ClinicalTrials.gov